Latest news with #Arbor
Yahoo
25-05-2025
- Business
- Yahoo
5 Bills Most Likely To Eat Into Your Paycheck Under Tariffs — and How To Cut Them
Tariffs on fuel, electricity infrastructure and imported goods are driving up the cost of regular bills, forcing families to get creative to afford the same items they usually buy or do without. We're a Family of 5 Living on One Salary: Try These: Even bills you don't typically associate with global trade, like power or streaming services, are being affected by these price increases. Here are the bills most likely to eat into your monthly paycheck and what you can do to cut costs. Tariffs on energy and fuel are significantly impacting consumers, particularly lower- and middle-income households. For instance, the 10% tariff on Canadian energy resources is raising costs for gasoline and other energy products, which indirectly increases transportation and heating expenses, according to George Carrillo, CEO of the Hispanic Construction Council (HCC), but also the former director of social determinants of health for the state of Oregon. 'Historically, a 25% rise in energy prices has felt more like a 30% increase for these households due to their relatively greater reliance on energy-intensive essentials,' he explained. This means families are paying more at the pump, in their heating bills, and even indirectly through transportation costs affecting goods and services. Read Next: Tariffs and 'ballooning transmission and distribution costs' have become a 'silent surcharge on every U.S. power bill,' according to Owen Quinlan, Head of Data at Arbor. 'These costs and debts roll into the delivery line of power bills, so households — roughly 40 % of national electricity demand — are funding both last century grid repairs and tomorrow's capacity build out at the same time,' he said. Residential supply rates are also spiking this summer, he said, 'with double digit hikes already locked in for large parts of Pennsylvania, Ohio and Illinois,' where supply hasn't caught up with demand. Meanwhile, the utility companies are pouring billions into storm preparation and long overdue infrastructure upgrades, and new tariffs on steel, aluminum and transformers could add up to $53 billion a year to sector costs, Quinlan said. 'Every extra dollar a utility spends on borrowing or upkeep shows up in some way or another on everyday American's power bills, and the squeeze will only widen if capital and [operating and management] costs keep climbing,' he explained further. To lower your energy bills, focus on efficiency, Carillo urged. 'Switching to LED bulbs, unplugging unused devices and using a programmable thermostat can all help. Consider improving insulation, sealing doors and windows, or upgrading to energy-efficient appliances to save in the long term.' Additionally, Quinlan recommended seeking rebates and incentives for home upgrades. 'There are a wide range of federal, state, and local incentives designed to lower the upfront cost of energy-efficient upgrades,' he noted. 'This includes things like heat pumps, weatherization, insulation, smart thermostats and even electric panel updates.' When tariffs drive up the costs of imported goods like food and fuel, the effects ripple down to other monthly expenses, Carrillo said. 'Groceries, for example, now cost 2.6% more on average, with fresh produce spiking over 5%,' he said. This is translating to households spending roughly $3,800 more annually on groceries, he noted. 'To save, focus on buying seasonal and locally grown produce, which can be fresher and cheaper,' Carrillo advised. 'Discount grocery stores and bulk buying options for staples like rice and canned goods are excellent for cutting costs.' Other strategies include using store loyalty programs and coupons, planning meals ahead to avoid impulse purchases and favoring more affordable protein alternatives like chicken or legumes. While not a bill, per se, items you rely upon in your home, such as appliances and electronics, are already 10-25% more expensive, Carrillo said, because they're often made from tariffed materials like steel and aluminum. 'These percentage increases quickly add up across a household budget, tightening financial flexibility.' 'Electronics, which rely on tariffed imported components, are becoming pricier, with some reports pointing to rising prices of phones, laptops and gaming consoles,' Carillo added. Subscription services, despite not being directly tariffed, are raising fees to cover operational overhead related to higher infrastructure costs, Carrillo said. 'These overlooked bills could unexpectedly strain budgets if not adjusted for.' Carrillo recommended some simple budgeting tips and tricks to make adjustments: Track: Track your expenses carefully to spot savings opportunities, like reducing dining out or unnecessary shopping. Prioritize: Prioritize essentials over discretionary spending by noting which items are needs and which are wants, deferring purchases like upgrades to electronics. Shop smarter: Use discounts, compare prices rigorously, and capitalize on cash-back and loyalty programs. Proactively employing these strategies can help households absorb the higher costs without significant sacrifices to their quality of life. These small, temporary adjustments can provide immediate relief in offsetting the rising costs caused by tariffs. More From GOBankingRates Surprising Items People Are Stocking Up On Before Tariff Pains Hit: Is It Smart? 6 Big Shakeups Coming to Social Security in 2025 This article originally appeared on 5 Bills Most Likely To Eat Into Your Paycheck Under Tariffs — and How To Cut Them Sign in to access your portfolio
Vancouver Sun
20-05-2025
- General
- Vancouver Sun
Cremated remains interred in wrong Surrey cemetery niche, owner seeks removal
The B.C. Supreme Court has been asked to resolve a dispute over a niche containing cremated remains in a Surrey cemetery after the niche was given in error to someone other than the woman who bought it. Mei Chiu in 2013 purchased the interment rights to the lawn niche from Arbor Memorial, owner of Valley View Memorial Gardens, for the spot in the Golden View Garden, according to a petition Arbor filed in B.C. Supreme Court. In 2017, Wing Chuen Chan bought a similar spot, also in Golden View Garden, it said. Start your day with a roundup of B.C.-focused news and opinion. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Sunrise will soon be in your inbox. Please try again Interested in more newsletters? Browse here. The two niches have identical numbers except for the last two numbers, and after Chan died in 2022, he was 'incorrectly interred' in Chiu's niche, it said. The cemetery said the mistake happened when staff members used an incorrect map and therefore counted from an incorrect landmark to locate the niche, according to the petition. The error wasn't noticed until last July when Chan's family requested carving on the tablet marking the location of Chan's urn, it said. Arbor Memorial requested permission from Chan's family to disinter the urn and relocate it to the niche he had purchased, but his widow, Wai Ping Kwok, refused, it said. Consumer Protection B.C., which governs burials, told Arbor in November it 'could not under any circumstances' without her consent disinter his remains, it said. Arbor again asked in March about the B.C. law regarding interred remains and was told 'Arbor and the director of Consumer Protection B.C.'s hands were tied without the consent of Mr. Chan's family to disinter his remains,' according to the petition. Arbor asked Chiu if she would like Chan's niche instead, but her son, Leonard, said she wanted that niche because of her wish to be buried near her husband and her father, it said. It also offered Chiu two side-by-side niches in a 'newer and nicer' location but her son refused, and he demanded Chan's remains be removed and that Arbor 'make a 'non-negotiable' payment of $20,000' to his mother. When he was told the Chan family wouldn't agree to relocating the urn, Leonard dropped the demand for the payment and said instead he would bring legal proceedings against Arbor. B.C.'s Cremation, Interment and Funeral Services Act prevents disinterment unless the cemetery operator receives a written request from the person with the 'right to control the disposition of the remains,' and the director of Consumer Protection approves it. It also says if a court intervenes in a disinterment, it 'must consider the feelings of those related to or associated with the deceased, with particular regard to the feelings of the spouse of the deceased.' The act also addresses correcting an error in interment, stating the cemetery at the request of the person responsible for the disposition of the remains has the right to 'disinter the remains from the wrong lot and reinter them in the correct lot, if the correct lot is available' or in another lot acceptable to the person making the request. In this case, it's the widow, Kwok, who 'has the control of the disposition' of her husband's remains and she hasn't requested they be relocated, so Arbor can't move them without a court order, according to the petition. Requests for comment left with the lawyer for Arbor Memorial, Valley View cemetery or with the director of Consumer Protection B.C. weren't returned on Monday. Neither Kwok nor Chiu could be reached.
Yahoo
15-05-2025
- Business
- Yahoo
Arbor Biotechnologies to Present Data on CNS Programs and Platform Advances at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
– Presentations demonstrate progress in advancing portfolio of CNS gene editing programs in SOD1 ALS and first data presented on company's Angelman syndrome program – Data showcase specificity characterization of Arbor's proprietary type V nucleases to have 10-fold greater sensitivity in off-target detection – Identification and characterization of first RT editor packageable in a single AAV CAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced the presentation of four posters showcasing Arbor's commitment to CNS diseases of high unmet need and advances in proprietary gene editing technology at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, taking place May 13-17 in New Orleans, Louisiana. CNS Program Presentations Presented data demonstrated preclinical proof-of-concept for Arbor's proprietary type V gene editing platform, which enables delivery of the nuclease and guide construct in a single AAV capsid, in amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) mutations. In vitro and in vivo data detailed the identification and characterization of nuclease and guide constructs targeting SOD1 that efficiently reduced SOD1 protein levels while maintaining low off-target liability. Assessment of top performing editing constructs in a fast-progressing preclinical mouse model of ALS prevented a decline in muscle function which is indicative of motor neuron preservation. Moreover, an ongoing survival study demonstrated an extension of survival by approximately 100 days compared to controls. Arbor's presentations at the meeting included the first public presentation of its differentiated gene editing approach to potentially enable long-term treatment of Angelman syndrome by reactivating the paternal copy of the UBE3A gene, which is normally silenced in Angelman patients. The gene editing approach was able to restore UBE3A protein levels in Angelman patient-derived neurons to or above levels found in neurotypical control neurons or greater. In a novel multi-electrode array assay, developed to evaluate neuron activity, Arbor demonstrated the ability to reverse the hyperexcitability and hypersynchrony phenotype demonstrated in Angelman syndrome neurons to levels observed in neurotypical control neurons. 'We are excited to share our progress in advancing our type V gene editing platform beyond the liver into two CNS diseases of high unmet medical need,' said John Murphy, Ph.D., Chief Scientific Officer at Arbor. 'These data support the continued development of these programs toward the clinic as novel therapeutic approaches with the potential to durably improve patient outcomes.' Arbor's Gene Editing Platform Presentations Building on an earlier oral presentation highlighting preclinical data for ABO-101 in PH1, a separate presentation further elaborated on the in-depth on- and off-target assessment of Arbor's proprietary engineered Cas12i2 type V nuclease. Data presented showed the consistency of Arbor's engineered Cas12i2 to generate 5-20 nucleotide deletions. The similarity between on- and off-target editing patterns enabled Arbor to develop and validate a robust statistical method for off-target analysis. The limit of detection of the verification workflow was shown to be 0.012%, which is 10-fold more sensitive than the industry standard for detection of off-target editing for Cas9-based programs. Arbor showcased this approach in the off-target analysis for ABO-101, with 80% on-target editing and no off-target edits detected above 0.1% in primary human hepatocytes (PHH) and human splenic endothelial cells (HSEC). An additional presentation detailed the first identification and characterization of novel small reverse transcriptase (RT) editors deliverable via a single adeno-associated virus (AAV) vector. Arbor demonstrated robust engineering of the small RT editors (sRTE) to substantially improve RT editing activity and broader targetability with the ability to make precise corrections in induced motor neurons. 'The advances in our platform technology support the sustainability of our gene editing discovery and development platform at Arbor,' said Devyn Smith, Ph.D., Chief Executive Officer at Arbor. 'The ability to increase the sensitivity of our off-target detection allows more rigorous evaluation of the specificity and safety profile of our nucleases prior to entering the clinic. In addition, our identification of, what is to our knowledge the first small RT editors capable of being delivered via single AAV, allows us to further expand potential therapeutic targets for future development.' Details for the poster presentations are as follows: Title: Abstract Number: 1100Session: Wednesday Poster ReceptionSession Date and Time: Wednesday, May 14, 2025, 5:30-7:00 PM CDTLocation: Poster Hall, Hall I2Presenter: Dan Brogan, PhD Title: Abstract Number: 1549Session: Thursday Poster ReceptionSession Date and Time: Thursday, May 15, 2025, 5:30-7:00 PM CDTLocation: Poster Hall, Hall I2Presenter: Adele Bubnys, PhD Title: Abstract Number: 1637Session: Thursday Poster ReceptionSession Date and Time: Thursday, May 15, 2025, 5:30-7:00 PM CDTLocation: Poster Hall, Hall I2Presenter: Ivan Kristanto Title: Abstract Number: 1923Session: Thursday Poster ReceptionSession Date and Time: Thursday, May 15, 2025, 5:30-7:00 PM CDTLocation: Poster Hall, Hall I2Presenter: Amrutha Pattamatta, PhD About ABO-101ABO-101 is a novel, investigational gene editing medicine designed to be a one-time liver-directed gene editing treatment that results in a permanent loss of function of the HAO1 gene in the liver to reduce PH1-associated oxalate production. ABO-101 is currently being evaluated for PH1 in the redePHine Phase 1/2 clinical study (NCT06839235). PH1 is a rare genetic disorder in which enzyme deficiencies in the liver lead to the overproduction and buildup of oxalate, resulting in kidney stones eventually leading to end stage kidney disease and systemic oxalosis. ABO-101 is designed to knock down HAO1 gene expression in the liver, thereby providing durable reduction in oxalate production. ABO-101 consists of a lipid nanoparticle (LNP), licensed from Acuitas Therapeutics, encapsulating messenger RNA expressing a novel Type V CRISPR Cas12i2 nuclease and an optimized guide RNA which specifically targets the human HAO1 gene. About Arbor Biotechnologies, Biotechnologies™, a clinical stage, next-generation gene editing company based in Cambridge, MA, is advancing a pipeline of novel gene editing therapeutics to address a wide range of genetic conditions – from the ultra-rare to the most common genetic diseases. The company's unique suite of optimized gene editors, which is capable of approaches ranging from gene knockout, excisions, reverse transcriptase editing, and large gene insertion, goes beyond the limitations of early editing technologies to unlock access to new gene targets and has fueled a robust pipeline of first-in-class assets focused on diseases of high unmet need. With Arbor's lead program, ABO-101 for the treatment of primary hyperoxaluria type 1, progressing into clinical trials, the company continues to focus its research and development efforts on genomic diseases of the liver and CNS for which there are no existing functional cures. For more information, please visit: Media Contact:Peg RusconiDeerfield Groupprusconi@
Yahoo
13-05-2025
- Business
- Yahoo
Arbor Biotechnologies to Present Preclinical Data for ABO-101 in PH1 at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
– Data from oral presentation supported ABO-101 IND and CTA approval for clinical assessment in primary hyperoxaluria type 1 (PH1) in the Phase 1/2 redePHine study in US and UK (NCT06839235) – Preclinical data demonstrate highly specific and durable editing of HAO1 with long-lasting reduction of urinary oxalate levels out to one-year post-single dose administration of ABO-101 – Non-human primate studies confirm preclinical efficacy and tolerability of ABO-101 with efficient editing of HAO1, reduced GO enzyme activity, and no clinical signs or adverse events – Progeny studies demonstrate the lack of germline transmission of the intended ABO-101 edit to Hao1 in over 500 pups CAMBRIDGE, Mass, May 13, 2025 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today presents IND- and CTA-enabling data for its lead clinical program, ABO-101 in primary hyperoxaluria type 1 (PH1) at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting in New Orleans, Louisiana. 'We are excited to showcase this robust preclinical data package which supported the IND clearance and CTA approval in the UK for our first clinical program' said Dan Ory, M.D., Chief Medical Officer at Arbor. 'This data increases our confidence in the potential for ABO-101 to provide a long-term clinically-meaningful treatment for PH1 patients, as we begin enrollment of our Phase 1/2 redePHine clinical study evaluating ABO-101 for the treatment of PH1, a rare genetic disorder with high unmet need'. In an oral presentation, Arbor showcased data supporting the therapeutic potential of ABO-101 for PH1 and its clinical evaluation in the redePHine clinical study (NCT06839235). The presented data demonstrated durable and efficient dose-dependent in vivo editing of Hao1 in the Agxt KO mouse model of PH1, resulting in a corresponding reduction of approximately 40% in urinary oxalate levels that was sustained out to 1-year post-administration of a single dose of ABO-101. Administration of ABO-101 to juvenile mice resulted in editing and oxalate reduction that persisted into adulthood. An additional study evaluating the potential of treated female mice to transmit the edit to their offspring demonstrated no transmission through the germline in over 500 pups. Data from non-human primate (NHP) studies confirmed the editing efficiency and tolerability of ABO-101 with no clinical signs or adverse events. Moreover, ABO-101 editing was shown to be highly specific to HAO1 in both primary human hepatocytes (PHH) and human splenic endothelial cells (HSEC) with no off-target editing detected above 0.07% at >1,500 potential sites, in an assay with a 10-fold greater sensitivity than reported industry standards for CRISPR nucleases. Further details on the off-target assessment of ABO-101 and the editing profile of Arbor's Type V nucleases will be included in a poster presentation during the Thursday poster session. Details for the oral presentation are as follows:Oral Presentation Title: Abstract Number: 44Session: Gene and Cell Therapy for Metabolic DiseasesSession Date and Time: Tuesday, May 13, 2024, 1:30-3:15 PM CDTLocation: Room 278-282Presenter: Tia DiTommaso, PhD Details for the poster presentation are as follows:Poster Title: Abstract Number: 1637Session: Thursday Poster ReceptionSession Date and Time: Thursday, May 15, 2024, 5:30-7:00 PM CDTLocation: Poster Hall, Hall I2Presenter: Ivan Kristanto About ABO-101ABO-101 is a novel, investigational gene editing medicine designed to be a one-time liver-directed gene editing treatment that results in a permanent loss of function of the HAO1 gene in the liver to reduce PH1-associated oxalate production. ABO-101 is currently being evaluated for PH1 in the redePHine Phase 1/2 clinical study (NCT06839235). PH1 is a rare genetic disorder in which enzyme deficiencies in the liver lead to the overproduction and buildup of oxalate, resulting in kidney stones eventually leading to end stage kidney disease and systemic oxalosis. ABO-101 is designed to knock down HAO1 gene expression in the liver, thereby providing durable reduction in oxalate production. ABO-101 consists of a lipid nanoparticle (LNP), licensed from Acuitas Therapeutics, encapsulating messenger RNA expressing a novel Type V CRISPR Cas12i2 nuclease and an optimized guide RNA which specifically targets the human HAO1 gene. About Arbor Biotechnologies, Biotechnologies™, a clinical stage, next-generation gene editing company based in Cambridge, MA, is advancing a pipeline of novel gene editing therapeutics to address a wide range of genetic conditions – from the ultra-rare to the most common genetic diseases. The company's unique suite of optimized gene editors, which is capable of approaches ranging from gene knockout, excisions, reverse transcriptase editing, and large gene insertion, goes beyond the limitations of early editing technologies to unlock access to new gene targets and has fueled a robust pipeline of first-in-class assets focused on diseases of high unmet need. With Arbor's lead program, ABO-101 for the treatment of primary hyperoxaluria type 1, progressing into clinical trials, the company continues to focus its research and development efforts on genomic diseases of the liver and CNS for which there are no existing functional cures. For more information, please visit: Media Contact:Peg RusconiDeerfield Groupprusconi@
Globe and Mail
09-04-2025
- Business
- Globe and Mail
Toll Brothers Offers New Move-In Ready Homes in Caldwell, Idaho
CALDWELL, Idaho, April 09, 2025 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation's leading builder of luxury homes, today announced that the company has a select number of move-in ready homes available in its two popular Caldwell, Idaho communities: Passero Ridge and Pradera. In addition to its build-to-order home sites in both communities, Toll Brothers offers move-in ready and quick move-in homes already under construction with Designer Appointed Features curated by professional Design Consultants at the Toll Brothers Design Studio. 'These two beautiful communities offer an array of luxury homes with options for every timeline in sought-after Caldwell,' said Ryan Hammons, Division President of Toll Brothers in Idaho. 'Our move-in ready homes are an incredible opportunity for customers who want to begin living in their new dream home as soon as possible.' At Toll Brothers' Passero Ridge and Pradera communities, residents will find Caldwell's ever-growing wine country is located just minutes away, while fishing, boating, and hiking are within reach at Lake Lowell. Passero Ridge, located just north of Lake Lowell's rustic shoreline, offers single-family quick move-in homes and move-in ready homes from the Arbor, Juniper, and Willow collections. The community offers scenic mountain views and spectacular amenities, including a pool, pool house, pickleball court, and playground. Homes at Passero Ridge range from 1,382 to 3,433+ square feet and are priced from $374,995. Offering large home sites and luxury quick move-in and move-in ready homes from the Brookside collection, Pradera features single-level home designs with open-concept living. Ranging from 2,128 to 2,668+ square feet, the homes offer high-end finishes and beautiful exterior design. Homes in Pradera are priced from $499,995. For more information on Passero Ridge, Pradera, or any of the 14 Toll Brothers communities available in Idaho, home shoppers are invited to call (208) 780-6729 or visit About Toll Brothers Toll Brothers, Inc., a Fortune 500 Company, is the nation's leading builder of luxury homes. The Company was founded 58 years ago in 1967 and became a public company in 1986. Its common stock is listed on the New York Stock Exchange under the symbol 'TOL.' The Company serves first-time, move-up, empty-nester, active-adult, and second-home buyers, as well as urban and suburban renters. Toll Brothers builds in over 60 markets in 24 states: Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Indiana, Maryland, Massachusetts, Michigan, Nevada, New Jersey, New York, North Carolina, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Virginia, and Washington, as well as in the District of Columbia. The Company operates its own architectural, engineering, mortgage, title, land development, smart home technology, and landscape subsidiaries. The Company also develops master-planned and golf course communities as well as operates its own lumber distribution, house component assembly, and manufacturing operations. Toll Brothers has been one of Fortune magazine's World's Most Admired Companies™ for 10+ years in a row, and in 2024 the Company's Chairman and CEO Douglas C. Yearley, Jr. was named one of 25 Top CEOs by Barron's magazine. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit From Fortune, ©2025 Fortune Media IP Limited. All rights reserved. Used under license. ameck@
